Form 4: Quest Diagnostics CEO Settles Performance Award

Quest Diagnostics CEO and President, J. E. Davis, acquired 51,652 shares from a performance stock award and subsequently disposed of 26,414 shares for tax withholding.

Summary

• J. E. Davis, CEO and President of Quest Diagnostics Inc. (DGX), acquired 51,652 shares of common stock on March 4, 2026.
• This acquisition was a settlement of a performance stock award, approved under Rule 16b-3(d).
• Concurrently, Davis disposed of 26,414 shares of common stock on the same date to cover tax withholding obligations related to the award settlement.
• Both transactions occurred at a price of $204.86 per share.
• Following these transactions, Davis beneficially owns 142,423 shares of Quest Diagnostics common stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting the successful achievement of performance targets by management, which is generally favorable for shareholders, despite the necessary tax-related share disposition.

Positives

• The acquisition of 51,652 shares indicates the successful vesting and settlement of a performance stock award, suggesting the company met specific performance criteria.
• The award aligns management's interests with shareholder value creation.

Negatives

• The disposition of 26,414 shares, even for tax purposes, reduces the direct ownership stake of the CEO.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that performance-based equity awards are a standard component of executive compensation packages across the healthcare diagnostics industry, designed to incentivize long-term performance and align executive interests with shareholder returns. The settlement of such an award suggests the company met its pre-defined performance targets.

Comparison to Industry Standards

• The structure of performance stock awards and subsequent tax-related dispositions is a common practice for executive compensation in large public companies, comparable to practices at peers like Laboratory Corporation of America Holdings (LH) or Eurofins Scientific.
• The specific number of shares and transaction value are unique to Quest Diagnostics and J. E. Davis's compensation structure, but the mechanism is standard.

Related Party Transactions

• The transactions involve the reporting person (J. E. Davis) and the issuer (Quest Diagnostics Inc.), which is a related party transaction, specifically related to executive compensation.

Stakeholder Impact

• Shareholders: The vesting of performance awards indicates management met performance goals, which is generally positive for shareholder value. The disposition for tax purposes is a routine event and not indicative of a lack of confidence.
• Employees: No direct impact on general employees is indicated.
• Management: J. E. Davis's compensation package is partially realized, reflecting past performance.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event (performance stock award settlement and tax withholding) and does not provide new information that would fundamentally alter the investment thesis for Quest Diagnostics. It confirms that performance targets were met, which is a positive, but the disposition for tax is standard. Therefore, a "hold" recommendation is appropriate as it doesn't present a strong buy or sell signal based solely on this filing.

Keywords

Quest Diagnostics, DGX, J. E. Davis, CEO, President, Form 4, Insider Transaction, Performance Stock Award, Equity Compensation, Stock Settlement, Tax Withholding, Beneficial Ownership